Counter Pulsation Devices Market By Product Type (External Counterpulsation Systems, Implantable/Wearable Devices); By Application (Chronic Angina Management, Heart Failure Therapy, Peripheral Vascular Disease Support); By End User (Hospitals, Cardiology Clinics, Outpatient Specialty Centers, Rehabilitation Facilities); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Counter Pulsation Devices Market: Guideline Changes, Equipment Replacement and EECP Utilization Shape Revenue Growth

The Global Counter Pulsation Devices Market is projected to expand at a CAGR of 6.5%, increasing from USD 1.92 billion in 2025 to USD 2.98 billion by 2032, according to Strategic Market Research.

 

Counter-pulsation devices are used to improve blood flow and support cardiac function, with Enhanced External Counterpulsation representing the most established non-invasive technology in this category. These systems are cleared by the U.S. Food and Drug Administration as Class II medical devices and are primarily used in patients with refractory chronic stable angina, acute myocardial infarction, cardiogenic shock, and congestive heart failure.

 

Commercially available and historically significant products include Vasomedical’s EECP platforms, such as the TS3 and TS4 models. These systems use inflatable cuffs positioned around the lower limbs, which apply pressure in sequence according to the patient’s electrocardiogram-based cardiac cycle. The CPCA2000 Counterpulsation System is another non-invasive external device cleared for the management of angina and for supporting patients with heart failure. The CardiAssist ECP System was among the earlier cleared counter-pulsation devices developed for acute myocardial infarction and cardiogenic shock applications.

 

Technology development has also included implantable counter-pulsation devices designed to increase blood flow during diastole. Investigational systems, including the Symphony implantable counter-pulsation device, explored the use of surgically implanted mechanical components positioned near the thoracic or aortic region. However, these implantable approaches remain limited to niche research and experimental applications when compared with widely adopted external counter-pulsation systems.

 

Current product development is increasingly centered on software-enabled improvements rather than major changes to the external device structure. Emerging systems are incorporating real-time pulse oximetry monitoring, automatic filtering of electrocardiogram interference, and patient-specific pressure control algorithms. These advancements are intended to improve treatment accuracy, patient safety, system responsiveness, and the overall effectiveness of counter-pulsation therapy.

 

IABP Use Narrows After the 2025 ACS Guideline

The 2025 ACC/AHA acute coronary syndromes guideline assigned routine IABP use in acute myocardial infarction with cardiogenic shock a Class 3 “no benefit” position because clinical trials did not demonstrate a mortality advantage. IABP remains reasonable for selected mechanical complications requiring temporary stabilization before surgery. Microaxial flow pumps received support for selected patients with severe or refractory shock.

Shock teams, interventional cardiologists and cardiac surgeons are now selecting IABP on a case-by-case basis rather than using it routinely across myocardial-infarction-related shock. Suppliers must focus on complex PCI, postcardiotomy low-output states, mechanical complications and transfers to tertiary cardiac centers. Total myocardial infarction admissions no longer provide a reliable measure of device demand.

More than 500,000 PCIs are performed annually in the United States and more than 2 million are performed globally. U.S. IABP utilization among PCI patients aged 65 or older was 356 uses per 10,000 procedures in 2021, equivalent to 3.56% in that cohort. Device revenue is therefore tied to high-risk case mix and hemodynamic instability rather than overall catheterization-laboratory volume.

A U.S. inpatient analysis recorded 1,254,358 cardiogenic-shock hospitalizations between 2004 and 2018. Adjusted in-hospital mortality declined from 49% to 37% during that period. Hospitals continue to invest in shock-care infrastructure, but IABP vendors now compete for a smaller group of cases involving bridge-to-surgery support, rapid deployment or transport continuity.

 

FDA Actions Accelerate IABP Replacement Decisions

Getinge’s Cardiosave quality issues created the largest recent competitive disruption in the invasive segment. In May 2024, the FDA advised U.S. facilities to transition to alternative devices where possible. Getinge initiated 12 U.S. Cardiosave recalls between January 2023 and April 2024, including eight Class I actions. The FDA received 2,964 Cardiosave medical-device reports during the preceding 12 months, including 15 reports involving serious injury or death.

Getinge subsequently paused U.S. promotion of Cardiosave and Cardiohelp. The company estimated that the affected hardware and consumables represented more than 60% of their combined U.S. market. Hospitals with large Getinge fleets began evaluating alternative consoles, backup equipment and revised service arrangements.

Teleflex entered this replacement cycle with the AC3 Range IABP after receiving FDA clearance in April 2025. The system supports ambulance, fixed-wing and rotary-wing transport. Community hospitals, transfer teams and specialist referral centers can use the same platform across different care settings, giving Teleflex access to systemwide contracts rather than isolated catheterization-laboratory purchases. Every console placement can also generate recurring demand for compatible balloon catheters.

Getinge submitted a new Cardiosave 510(k) application in June 2026. FDA clearance would restore competition in U.S. hardware tenders and give hospitals greater leverage over console, catheter and service pricing. Teleflex has gained time to establish reference accounts, while Getinge retains a large installed base and established catheter relationships. Replacement tenders placed between 2025 and 2027 could determine consumable and service contracts for several subsequent years.

 

Recalls Shift Procurement Toward Lifecycle Contracts

One Cardiosave Class I correction covered 4,586 U.S. devices. Teleflex’s 2024 recall covered 16,959 FiberOptix and UltraFlex catheter kits distributed between May 2022 and April 2024. The FDA reported 322 complaints, 31 injuries and three deaths potentially associated with the Teleflex catheter issue.

Hospital procurement teams now evaluate service response, loaner availability, software updates, catheter supply and backup inventory alongside the purchase price. Console failures and catheter defects can both interrupt critical-care workflows, giving national service coverage greater influence in supplier selection. Newly cleared manufacturers face a higher entry barrier because regulatory approval does not provide the field-service capacity needed to support large hospital networks.

Console pricing increasingly reflects expected catheter and maintenance revenue. Suppliers can discount reusable equipment when a placement secures several years of disposable-catheter demand. Hospitals are responding with total-cost contracts that connect catheter pricing, maintenance charges and replacement guarantees to the number of installed consoles.

 

EECP Revenue Depends on Reimbursed Treatment Volume

Approximately 20.5 million U.S. adults had coronary heart disease during 2017–2020, while global ischemic heart disease prevalence reached 254.3 million cases in 2021. EECP addresses only a small part of these populations because treatment is generally limited to patients with persistent symptoms and no suitable revascularization option.

U.S. refractory-angina prevalence is estimated at 600,000 to 1.8 million patients, with approximately 75,000 new diagnoses annually. Between 7% and 14% of patients undergoing angiography may have anatomy unsuitable for revascularization. Only patients who meet symptom-severity, clinical and payer requirements can move from this referral population into reimbursed treatment.

The 2023 chronic coronary disease guideline gives EECP a Class 2b recommendation for symptom relief in patients with refractory angina and no other treatment options. Medicare coverage is limited to disabling Class III or IV angina when PCI or CABG is unsuitable. A standard course generally contains 35 one-hour sessions. Treatment-center revenue therefore depends on qualified referrals, course completion and daily system throughput.

CMS approved a nationwide Recovery Audit Contractor review for G0166 external counterpulsation claims in March 2026. Providers now face greater payment-recovery risk when patient eligibility or session records are incomplete. Vendors that provide documentation tools, reporting support and staff training can justify higher pricing by reducing billing risk across the full treatment course.

EECP Global reports more than 5,000 systems in over 4,000 hospitals across more than 60 countries and more than 10 million cumulative patients treated. Vaso’s equipment segment generated USD 2.44 million in 2025. First-quarter 2026 revenue increased 27% to USD 560,000, mainly because of higher deliveries in China.

Pression received FDA clearance for the Wave PRO External Counter-Pulsation System in December 2025. Pression’s entry increases equipment choice in the United States, while Vaso’s China deliveries point to distributor-led growth outside the U.S. market. Installed-system counts alone do not determine revenue; active treatment courses and recurring facility utilization determine whether equipment placements generate sustainable returns.

 

Counter Pulsation Devices Market Segment Revenue Estimation and Forecast

The following shares, revenues and growth rates are Strategic Market Research analyst-derived estimates reconciled with the approved USD 1.92 billion market value for 2025 and USD 2.98 billion forecast for 2032.

The requested Implantable/Wearable Devices category includes temporary invasive counterpulsation systems and portable or wearable configurations. External Counterpulsation Systems include fixed cuff-based ECP and EECP platforms.

By Product Type

External Counterpulsation Systems accounted for an estimated 72.0% of market revenue in 2025, equal to USD 1.382 billion. The segment is projected to expand at a CAGR of 5.6% and reach USD 2.026 billion by 2032.

An established installed base, Medicare reimbursement for severe refractory angina and recurring 35-session treatment courses support the segment’s leading position. Coverage restrictions and limited guideline support keep growth below the total market rate. Pression’s Wave PRO clearance, Vaso’s commercial activity and EECP Global’s international distribution are widening equipment choice, but revenue per installation will depend on patient throughput.

Implantable/Wearable Devices represented an estimated 28.0% of the market in 2025, equivalent to USD 0.538 billion. The segment is forecast to grow at 8.5% annually and reach USD 0.954 billion by 2032.

Teleflex’s AC3 Range launch and Getinge’s new Cardiosave submission are directing supplier investment toward portable and transport-compatible acute-care systems. Replacement purchases, backup-capacity requirements and interhospital transport applications are expected to raise the segment’s market share to approximately 32.0% by 2032.

 

By Application

Chronic Angina Management generated an estimated 56.0% of market revenue in 2025, equivalent to USD 1.075 billion. The segment is forecast to grow at a CAGR of 5.1% and reach USD 1.520 billion by 2032.

Medicare reimbursement and the large U.S. refractory-angina population support the application’s leading position. Its share is expected to decline to approximately 51.0% by 2032 because the established angina pathway will expand more slowly than hospital-based circulatory-support applications.

Heart Failure Therapy accounted for an estimated 30.0% of the market in 2025, equal to USD 0.576 billion. Revenue is projected to increase at a CAGR of 8.4% and reach USD 1.013 billion by 2032.

Temporary IABP support is used in selected low-output states, perioperative instability and complications of heart failure. Approximately 55.5 million people were living with heart failure globally in 2021, although only a small clinical subset becomes eligible for counterpulsation. Investment in advanced heart-failure programs and higher-acuity hospital infrastructure is expected to raise the application’s share to approximately 34.0% by 2032.

Peripheral Vascular Disease Support represented an estimated 14.0% of 2025 revenue, equivalent to USD 0.269 billion. The segment is forecast to grow at 7.5% annually and reach USD 0.447 billion by 2032.

More than 230 million people are estimated to live with peripheral arterial disease globally. Counterpulsation is not a standard first-line treatment for this population. Revenue growth will depend on stronger clinical outcomes, broader physician acceptance and payer recognition rather than the size of the underlying disease population.

 

By End User

Hospitals held an estimated 51.0% share in 2025, equal to USD 0.979 billion. Revenue is forecast to grow at 4.9% and reach USD 1.371 billion by 2032.

Cardiac surgery, intensive care, emergency transfer and complex PCI keep hospitals as the largest end-user group. Guideline pressure on routine IABP deployment will limit volume growth. Spending will concentrate in tertiary centers replacing affected consoles, purchasing transport-ready systems and negotiating long-term catheter and maintenance contracts.

Cardiology Clinics generated an estimated 23.0% of 2025 revenue, equivalent to USD 0.442 billion. The segment is projected to grow at a CAGR of 7.1% and reach USD 0.715 billion by 2032.

Clinics control diagnosis, medication management, referral and follow-up for many refractory-angina patients. Practices with affiliated ECP programs can retain more of the treatment pathway and convert qualified patients into completed courses.

Outpatient Specialty Centers accounted for an estimated 17.0% of the market in 2025, equal to USD 0.326 billion. The segment is forecast to record the fastest end-user CAGR of 9.0%, reaching USD 0.596 billion by 2032.

Specialty centers can operate systems for repeated daily sessions and distribute compliance costs across a larger number of treatment courses. The CMS claims audit is likely to shift more patients toward high-volume operators with stronger documentation and billing controls. Their market share is expected to reach approximately 20.0% by 2032.

Rehabilitation Facilities represented an estimated 9.0% of market revenue in 2025, equivalent to USD 0.173 billion. The segment is projected to expand at 8.1% annually and reach USD 0.298 billion by 2032.

Cardiovascular rehabilitation programs can add ECP services for eligible patients already receiving supervised recovery and functional support. Narrow reimbursement and referral criteria are expected to keep the segment below 10% of total revenue during most of the forecast period.

 

By Geography

North America accounted for an estimated 42.0% of the market in 2025, equal to USD 0.806 billion. The region is projected to grow at 5.4% and reach USD 1.162 billion by 2032.

Medicare reimbursement, advanced cardiac infrastructure and the Getinge-Teleflex replacement cycle keep North America in the leading position. Routine IABP use faces guideline pressure, while EECP reimbursement remains limited to severe refractory angina. Regional growth will therefore come mainly from replacement systems, catheter contracts and treatment-center utilization.

Europe represented an estimated 28.0% of 2025 revenue, equivalent to USD 0.538 billion. The region is forecast to grow at a CAGR of 5.9% and reach USD 0.805 billion by 2032.

European cardiology infrastructure and the population of patients unsuitable for further revascularization support continued demand. Differences in reimbursement, referral behavior and treatment-center capacity will prevent uniform adoption across national markets.

Asia Pacific generated an estimated 21.0% of market revenue in 2025, equal to USD 0.403 billion. The region is projected to record the fastest CAGR of 9.2% and reach USD 0.745 billion by 2032.

Vaso’s 27% first-quarter 2026 increase in equipment revenue came mainly from higher product deliveries in China. New cardiac hospitals, private healthcare investment and expanding tertiary-care capacity are supporting distributor-led equipment sales even without uniform public reimbursement.

Latin America represented an estimated 5.0% of the market in 2025, equal to USD 0.096 billion. The region is forecast to grow at 6.5% and reach USD 0.149 billion by 2032.

The Middle East and Africa accounted for an estimated 4.0% of 2025 revenue, equivalent to USD 0.077 billion. The regional market is also projected to expand at 6.5%, reaching USD 0.119 billion by 2032.

Private hospitals, tertiary cardiac centers and large urban healthcare networks will account for most purchases across Latin America, the Middle East and Africa. Capital availability, specialist staffing and local distributor service capacity will determine whether facilities can maintain invasive support systems or operate recurring EECP programs.

 

Forecast Interpretation

Between 2025 and 2032, IABP revenue will shift toward equipment replacement, patient transport, complex interventions, disposable catheters and maintenance contracts. EECP revenue will depend on converting qualified refractory-angina patients into completed 35-session courses while meeting stricter documentation requirements.

IABP suppliers need reliable consoles, continuous catheter supply and rapid field service. EECP suppliers need qualified referral networks, reimbursement support and high treatment-system utilization. The projected 55.2% increase in market value depends on higher revenue per installed system and support episode rather than broad expansion of routine clinical eligibility.

 

Counter Pulsation Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.92 Billion
Revenue Forecast in 2032	USD 2.98 Billion
Overall Growth Rate	CAGR of 6.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	External Counterpulsation Systems, Implantable/Wearable Devices
By Application	Chronic Angina Management, Heart Failure Therapy, Peripheral Vascular Disease Support
By End User	Hospitals, Cardiology Clinics, Outpatient Specialty Centers, Rehabilitation Facilities
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Replacement of recalled and aging IABP consoles, rising demand for transport-compatible circulatory-support systems, recurring catheter and lifecycle-service contracts, reimbursed EECP treatment utilization, and expansion of tertiary cardiac-care infrastructure
Customization Option	Available upon request